Northpond and Cowen lead Series A round for Aro Biotherapeutics
Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, has raised $88 million in Series A financing.
Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, has raised $88 million in Series A financing.